Open Access

Expression of vascular endothelial growth factor receptor in thymic epithelial tumors

  • Authors:
    • Kensuke Chiba
    • Takayuki Murase
    • Keisuke Yokota
    • Tsutomu Tatematsu
    • Risa Oda
    • Ryuji Nakamura
    • Shogo Yobita
    • Takatsugu Takano
    • Katsuhiro Okuda
  • View Affiliations

  • Published online on: June 18, 2024     https://doi.org/10.3892/ol.2024.14516
  • Article Number: 383
  • Copyright: © Chiba et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Thymic epithelial tumors (TETs) are rare and the major symptoms are not obvious until the tumor progresses to a relatively large size and compresses the surrounding organs. As its growth is aggressive and it metastasizes to distant organs, it is important to find novel effective therapies. Lenvatinib, a vascular endothelial growth factor receptor (VEGFR) inhibitor, is approved as a drug therapy for thymic carcinoma (TC); however, although it is a molecular targeted therapy, there are no obvious predictors of therapeutic efficacy. The present study aimed to assess the association between clinicopathological factors and the protein expression of VEGFR, which is associated with tumor aggressiveness and the efficacy of VEGFR inhibitors. The VEGFR‑2 protein expression was evaluated in 144 patients with TETs who underwent surgical resection. The present study assessed whether the expression of VEGFR‑2 protein was associated with TET classification and pathological stage, progression‑free survival and overall survival (OS). A total of 94 cases (65.2%) were positive for VEGFR‑2 protein. The expression of VEGFR‑2 was higher in the more aggressive type B3 thymoma and TC (88.5%) than in types A, AB, B1 and B2 thymoma (60.2%). The 5‑year OS rate for the overall population was 53.1%. The 5‑year OS rates of patients with negative VEGFR‑2 staining score values (66.5%) were significantly longer than in patients with positive VEGFR‑2 staining score values (42.5%; P=0.000078). Furthermore, the pathological stage was the only factor significantly associated with OS in multivariate analysis. The results of the present study suggest the possibility that the indications for VEGF inhibitor therapy could be extended to type B3 thymoma.
View Figures
View References

Related Articles

Journal Cover

August-2024
Volume 28 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Chiba K, Murase T, Yokota K, Tatematsu T, Oda R, Nakamura R, Yobita S, Takano T and Okuda K: Expression of vascular endothelial growth factor receptor in thymic epithelial tumors. Oncol Lett 28: 383, 2024.
APA
Chiba, K., Murase, T., Yokota, K., Tatematsu, T., Oda, R., Nakamura, R. ... Okuda, K. (2024). Expression of vascular endothelial growth factor receptor in thymic epithelial tumors. Oncology Letters, 28, 383. https://doi.org/10.3892/ol.2024.14516
MLA
Chiba, K., Murase, T., Yokota, K., Tatematsu, T., Oda, R., Nakamura, R., Yobita, S., Takano, T., Okuda, K."Expression of vascular endothelial growth factor receptor in thymic epithelial tumors". Oncology Letters 28.2 (2024): 383.
Chicago
Chiba, K., Murase, T., Yokota, K., Tatematsu, T., Oda, R., Nakamura, R., Yobita, S., Takano, T., Okuda, K."Expression of vascular endothelial growth factor receptor in thymic epithelial tumors". Oncology Letters 28, no. 2 (2024): 383. https://doi.org/10.3892/ol.2024.14516